eli lilly retatrutide trials Lilly's cuts weight by 17% in diabetes trial Eli Lilly's Next-Gen Obesity Drug

Hepatic and Metabolic Benefits A MAFLD/MASLD (metabolic dysfunction-associated steatotic liver disease) sub-study of the Phase 2 obesity trial reported that over 85% of participants on the highest retatrutide doses achieved more than 30% reduction in liver fat content measured by MRI, with many reaching complete resolution of steatosis

The session used the earliest available published data for CT-388 (24-week interim from ADA/ENDO 2024) and projected a 48-week plateau of 24 to 26% based on trajectory extrapolation from tirzepatide's weight-loss kinetics

2003, 9: BR131-BR135

This does not mean the findings are wrong